Droperidol (Inapsine): How This Injection Works for Nausea, Heart Rules, and Why It Is Not a Telehealth Medicine

Last updated: August 24, 2026

Droperidol is a butyrophenone neuroleptic given only as an injection. The historic brand is Inapsine. Vials typically hold 2.5 mg per mL. It is not a controlled substance. The FDA label reserves it to reduce nausea and vomiting tied to surgery or diagnostic procedures, and only after other treatments fail or cannot be used at an effective dose.

This guide covers what droperidol treats, how adult and pediatric dosing usually starts, why a 12-lead ECG comes first, and why a video visit cannot give this drug. It is educational, not a diagnosis or a promise that any plan will pay for a specific medicine.

See if you may qualify for online mental health care →

What is droperidol?

The DailyMed droperidol injection label (updated March 20, 2023; American Regent) describes a sterile solution for intravenous or intramuscular use only. Each mL contains 2.5 mg of droperidol. DEA schedule: none. Marketing status: ANDA. It is labeled as a neuroleptic (tranquilizer).

Mayo Clinic (portions last updated August 1, 2026) states droperidol injection is used to prevent nausea and vomiting that may occur after surgery or diagnostic procedures. A nurse or other trained professional gives it in a hospital as a shot into a muscle or a vein. Brand name in the U.S.: Inapsine. Safety and efficacy are not established under age 2.

StatPearls on antiemetic medications (September 26, 2022) notes that droperidol and haloperidol have proven efficacy as antiemetics, but side-effect profiles pushed them out of routine use for many teams. StatPearls on neuroleptic medications (February 21, 2024) adds that clinicians sometimes use IV droperidol or IV haloperidol for psychosis or delirium in acute medical settings. Those uses sit outside the U.S. labeled indication for perioperative nausea.

What does droperidol treat?

DailyMed indication: reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.

The boxed warning and contraindications narrow that further. Reserve droperidol for people who fail other adequate treatments, either because those drugs do not work well enough or because side effects block an effective dose. DailyMed says it is not recommended for any use other than perioperative nausea and vomiting in that setting.

Clinically, teams still discuss droperidol for acute agitation in emergency departments. That is off-label in the United States. Off-label use needs a clear reason, ECG capacity, and a discussion of alternatives. A telehealth visit is the wrong setting for an IM/IV drug with a QT boxed warning.

Browse conditions and next steps →

How do clinicians give droperidol?

DailyMed: individualize the dose. Age, weight, physical status, other drugs, the type of anesthesia, and the procedure all matter. Monitor vital signs and ECG routinely.

• Adults: Maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses may be given to reach the desired effect. Give extra doses with caution, and only if the potential benefit outweighs the risk.
• Children 2 to 12 years: Maximum recommended initial dose is 0.1 mg/kg, taking age and other clinical factors into account. Extra doses follow the same caution rule.
• Under 2 years: Safety is not established (DailyMed and Mayo Clinic).

Onset after a single IM or IV dose is 3 to 10 minutes. Peak effect may take up to 30 minutes. Tranquilizing and sedative effects generally last 2 to 4 hours. Changes in alertness may last as long as 12 hours.

DailyMed also tells clinicians to start low and raise with caution. Reduce the first dose in elderly, debilitated, and other poor-risk patients. Lower initial opioid doses when opioids are also needed.

There is no home tablet. There is no refill you pick up after a video visit. This drug stays in a monitored setting.

Why does an ECG come first?

DailyMed boxed warning: cases of QT prolongation and/or torsade de pointes have been reported at doses at or below recommended doses. Some cases occurred in people with no known risk factors. Some were fatal.

Because of serious proarrhythmic effects and death, reserve droperidol for people who already failed other adequate treatments. All patients should have a 12-lead ECG before the dose to check for a prolonged QT interval (QTc greater than 440 msec in males or 450 msec in females). If QT is already long, do not give droperidol. If a clinician still judges that benefit outweighs risk, monitor the ECG before treatment and for 2 to 3 hours after the last dose.

DailyMed cites a study of 40 patients without known heart disease who had extracranial head and neck surgery. Within 10 minutes, median QTc rose 37, 44, and 59 msec at 0.1, 0.175, and 0.25 mg/kg. Post-marketing reports include torsade, ventricular arrhythmia, cardiac arrest, and death. At least one nonfatal torsade case was confirmed by rechallenge.

Contraindications include known or suspected QT prolongation, including congenital long QT syndrome, and known hypersensitivity.

Use extreme caution when risk factors for long QT are present: congestive heart failure, bradycardia (DailyMed flags less than 50 bpm), diuretic use, cardiac hypertrophy, low potassium, low magnesium, other QT-prolonging drugs, age over 65, alcohol abuse, and agents such as benzodiazepines, volatile anesthetics, and IV opiates. Mayo Clinic also lists congenital long QT and QT prolongation as reasons not to use the drug, and flags pheochromocytoma, heart disease, and kidney or liver disease as extra cautions.

What else can go wrong?

Common somatic effects on the DailyMed label: mild to moderate hypotension and tachycardia, which usually settle without treatment. If blood pressure stays low, treat possible hypovolemia with IV fluid. Keep fluids and other countermeasures ready. Do not use epinephrine as the pressor of first choice if droperidol’s alpha blockade is in play; epinephrine may paradoxically drop blood pressure further.

Common behavioral effects: dysphoria, postoperative drowsiness, restlessness, hyperactivity, and anxiety. Those can mean the dose was too low or they can mean akathisia. Look for dystonia, akathisia, and oculogyric crisis. Anticholinergic drugs often control true extrapyramidal symptoms.

Other reported effects: postoperative hallucinatory episodes (sometimes with brief depression), anaphylaxis, dizziness, chills or shivering, laryngospasm, and bronchospasm. Combining droperidol with fentanyl or other parenteral analgesics has been followed by high blood pressure.

Very rare reports of neuroleptic malignant syndrome (altered consciousness, muscle rigidity, autonomic instability) appear on the label. In the perioperative period it can be hard to tell NMS from malignant hyperthermia. DailyMed says to consider prompt dantrolene if temperature, heart rate, or carbon dioxide production rise.

Mayo Clinic also lists blurred vision, sudden dizziness on standing, sweating, trouble breathing or swallowing, rash or hives, chest pain, fainting, irregular heartbeat, drooling, shuffling walk, and twisting movements.

Overdose is an extension of the same effects, including QT prolongation and torsade. DailyMed treatment notes: support breathing for 24 hours of observation, keep the person warm, replace volume if blood pressure is low, and use an anticholinergic for significant extrapyramidal reactions. Poison control: 1-800-222-1222. Collapse, seizure, or trouble breathing is 911.

DailyMed does not recommend use in labor and delivery. It is not known whether droperidol passes into human milk; use caution if a nursing parent receives it.

When is telehealth enough?

A video visit can review nausea history, current medicines (including other QT-prolonging drugs), whether a first-line antiemetic already failed, and whether someone needs in-person evaluation. A remote clinician cannot give IM or IV droperidol, cannot run the required 12-lead ECG in the visit itself, and cannot watch the tracing for 2 to 3 hours afterward.

Telehealth is a poor fit when nausea follows anesthesia, when QT is already long, when agitation or psychosis needs a monitored injection, or when NMS, dystonia, or arrhythmia symptoms appear. Those need in-person or emergency care.

For ongoing mental health care that does not require an injectable neuroleptic, a planned video visit may still help with evaluation and follow-up of other options.

HHS telehealth policy (updated February 5, 2026): Medicare patients can permanently receive behavioral health telehealth in the home. An in-person visit within six months of an initial Medicare behavioral telehealth service is not required through December 31, 2027.

Klarity Health has 2,000+ licensed providers. Many visits happen online. Coverage varies by plan. Verify benefits before you book. This is not a promise that droperidol will be prescribed or that any insurer will pay for it. Klarity visits do not replace hospital or emergency care for this injection.

See online anxiety treatment options → · Browse conditions →

Insurance and next steps

Hospital and facility claims typically carry droperidol as part of a procedure or emergency visit, not as a retail pharmacy fill. Many commercial and Medicare plans may cover a separate telehealth mental health visit. Coverage varies by plan, state, and formulary. Ask the plan about medical necessity and site-of-care rules before you assume a visit or a drug will be paid.

If you or someone you know is in crisis, call or text 988 or chat at 988lifeline.org.

Disclaimer: This article is for education. It is not medical advice, a diagnosis, or a guarantee of insurance coverage. Talk with a licensed clinician about your own care. Coverage varies by plan. Verify benefits before booking.